Immune response to racotumomab in a child with relapsed neuroblastoma

Immune response to racotumomab in a child with relapsed neuroblastoma

Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-gly...

Full description

Bibliographic Details
Main Authors: CLAUDIA VANESA SAMPOR, Marcelo David Guthmann, Alejandra eScursoni, Walter eCacciavillano, Ana eTorbidoni, Laura eGalluzzo, Sandra eCamarero, Jessica eLopez, Maria Teresa eGarcia de Davila, Leonardo eFainboim, Guillermo eChantada
Format: Article
Language:English
Published: Frontiers Media S.A. 2012-12-01
Series:Frontiers in Oncology
Subjects:
Immunotherapy
Neuroblastoma
monoclonal antibodies
ganglioside
racotumomab.
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00195/full
Description
Summary:Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides, eliciting an immune response in a child with relapsed neuroblastoma expressing the NeuGcGM3 ganglioside.
ISSN:2234-943X

Similar Items